看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
' B: z0 w0 F Y% H& k6 @
( _; o, M( v4 Z$ H) a
6 X( O3 |0 N H" s" y! i8 @Currently available feasibility data for possible combination strategies.
4 ~% B) Q0 m+ e————————————————————————————————
! J/ C7 h! S- w9 i: b- P; uCombination Feasibility according to preliminary data
% F/ s6 O( G0 t* O1 ]! v——————————————————————————————————
* K8 p: h. s4 ABevacizumab + sorafenib Yes, reduced dose : k4 ~, C9 r$ X
Bevacizumab + sunitinib† No ( B+ z5 R4 h. H+ K8 J# k+ C
Bevacizumab + temsirolimus Yes ( a- F3 b- O. \6 x% t
Bevacizumab + everolimus Yes
% _& C- D, ?: J$ t; [Sorafenib + sunitinib ?
3 X) r+ i( o1 Q* e1 `6 d/ ASorafenib + temsirolimus Yes, reduced dose
|( p, K l6 j/ j! g7 U7 USorafenib + everolimus Yes, reduced dose
. d" x' d5 [2 U; l" G, [4 f _ GSunitinib + temsirolimus† No 8 c2 h' w5 e( \( I, k$ _
Sunitinib + everolimus ?
: _6 d2 W: o$ Y' n4 F! |. }Temsirolimus + everolimus ? 7 X# k) l5 e# a" C( C
————————————————————2 p8 H' z& ?0 f; P6 H
†Led to US FDA warning.
+ p( b0 e7 ?5 o- J3 I, }# E?: As yet unattempted combination." U% Q W; b6 x! k9 Z! L! r; Y
|
显身卡
